Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes

Diabetes Care

Volumn 26, Issue 11, 2003, Pages 3087-3092

  Danne, Thomas ^a   Lüpke, Kerstin ^a   Walte, Kerstin ^a   Von Schuetz, Wolfgang ^a   Gall, Mari Anne ^b  

^a KINDERKRANKENHAUS AUF DER BULT   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; ISOPHANE INSULIN;

ADOLESCENT; ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CARRIER PROTEINS; CHILD; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; MALE; MIDDLE AGED;

EID: 0242300708     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.11.3087     Document Type: Article

References (35)

1. Danne T, Kordonouri O, Hovener G, Weber B: Diabetic angiopathy in children. Diabet Med 14:1012-1025, 1997
2. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV: Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 139:804-812, 2001
3. Heinemann L, Richter B: Clinical pharmacology of human insulin. Diabetes Care 16 (Suppl. 3):S90-S100, 1993
4. Matyka K, Ford-Adams M, Dunger DB: Hypoglycaemia and counterregulation during childhood. Horm Res 57 (Suppl. 1):85-90, 2002
5. Heinemann L: Variability of insulin absorption and insulin action. Diabetes Technol Ther 4:673-682, 2002
6. Owens D, Zinman B, Bolli G: Insulins today and beyond. Lancet 358:739-746, 2001
7. Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO: Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. Lancet 354:1604-1607, 1999
8. Lindholm A: New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol 16:475-492, 2002
9. Chase HP, Lockspeiser T, Peery B, Shepherd M, MacKenzie T, Anderson J, Garg SK: The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 24:430-434, 2001
10. Danne T, Deiss D, Hopfenmuller W, von Schutz W, Kordonouri O: Experience with insulin analogues in children. Horm Res 57 (Suppl. 1):46-53, 2002
11. Mohn A, Dunger DB, Chiarelli F: The potential role of insulin analogues in the treatment of children and adolescents with type 1 diabetes mellitus. Diabetes Nutr Metab 14:349-357, 2001
12. 125I-labeled insulin glargine (HOE 901) in healthy men. Diabetes Care 23:813-819, 2000
13. Heineman L, Linkeschova R, Rave K, Homplesch B, Sedlak M, Heise T: Time-action profile of the long-acting insulin analogue insulin glargine (HOE 901) in comparison with those of NPH insulin and placebo. Diabetes Care 23:644-649, 2000
14. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog insulin glargine, NPH insulin, and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142-2148, 2000
15. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Ribel U, Markussen J: Albumin binding and time action of acylated insulins in various species. J Pharm Sci 85:304-308, 1996
16. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T: Time-action profile of the soluble, fatty acid acylated, long-acting insulin analog NN304. Diabet Med 16:332-338, 1999
17. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M: Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 24:296-301, 2001
18. Roberts A, Standl E, Bayer T, Munksgaard E, Lang H: Efficacy and safety of 6-month treatment with insulin detemir in type 1 diabetic patients on a basal-bolus regimen (Abstract). Diabetologia 44 (Suppl. 1): A207, 2001
19. Vague P, Selam J-L, Skeie S, De Leeuw I, Elte JWF, Haarh H, Kristensen A, Draeger E: Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycaemia compared to NPH insulin in patients with type 1 diabetes on basal-bolus regimen with pre-meal insulin aspart. Diabetes Care 26:590-596, 2003
20. Declaration of Helsinki: Recommendations guiding medical physicians in biomedical research involving human subjects. JAMA 277:925-926, 1997
21. International Conference of Harmonisation (ICH): Topic E6: Harmonised tripartite guidelines for good clinical practice, step 5. Consolidated Guideline 1.5.96. Federal Register 62:25691-25709, 1997
22. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Røder ME: Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 39:578-582, 1993
23. Mortensen H, Lindholm A, Olsen B, Hylleberg B: Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 159:483-488, 2000
24. Acerini CL, Cheetham TD, Edge JA, Dunger DB: Both insulin sensitivity and insulin clearance in children and young adults with type I (insulin-dependent) diabetes vary with growth hormone concentrations and with age. Diabetologia 43:61-68, 2000
25. Mohn A, Strang S, Wernicke-Panten K, Lang AM, Edge JA, Dunger DB: Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care 23:557-559, 2000
26. Mortensen HB, Robertson KJ, Aanstoot HJ, Danne T, Holl RW, Hougaard P, Atchison JA, Chiarelli F, Daneman D, Dinesen B, Dorchy H, Garandeau P, Greene S, Hoey H, Kaprio EA, Kocova M, Martul P, Matsuura N, Schoenle EJ, Sovik O, Swift PG, Tsou RM, Vanelli M, Aman J: Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries: Hvidore Study Group on Childhood Diabetes. Diabet Med 15:752-759, 1998
27. Shalwitz R, Farkas-Hirsch R, White N, Santiago J: Prevalence and consequences of nocturnal hypoglycemia among conventionally treated children with diabetes mellitus. J Pediatr 116:685-689, 1990
28. Limbert C, Schwingshandl J, Haas J, Roth R, Borkenstein M: Severe hypoglycemia in children and adolescents with IDDM: frequency and associated factors. J Diabetes Complications 7:216-220, 1993
29. Porter P, Byrne G, Stick S, Jones T: Nocturnal hypoglycaemia and sleep disturbances in young teenagers with insulin dependent diabetes mellitus. Arch Dis Child 75:120-123, 1996
30. Beregszaszi M, Tubiana-Rufi N, Benali K, Noel M, Bloch J, Czernichow P: Nocturnal hypoglycemia in children and adolescents with insulin-dependent diabetes mellitus: prevalence and risk factors. J Pediatr 131(Pt 1):2-4, 1997
31. Rewers A, Chase HP, Mackenzie T, Walravens P, Roback M, Rewers M, Hamman RF, Klingensmith G: Predictors of acute complications in children with type 1 diabetes. JAMA 287:2511-2518, 2002
32. Monaco L, Geffken G, Silverstein J: Accuracy of injection site identification among children with insulin dependent diabetes mellitus: a comparison of traditional and new visual aids. Clin Pediatr (Phila) 35:191-197, 1996
33. Stewart N, Darlow B: Insulin loss at the injection site in children with type 1 diabetes mellitus. Diabet Med 11:802-805, 1994
34. Kordonouri O, Lauterborn R, Deiss D: Lipohypertrophy in young patients with type 1 diabetes (Letter). Diabetes Care 25:634, 2002
35. Strange P, McGill J, Mazzeo M: Reduced pharmacokinetic variability of a novel, long-acting insulin analog (Abstract). Diabetes 48 (Suppl. 1):A103, 1999